Terumo Corp stock (JP3443600006): Earnings in focus as shares trade near 52-week lows

Terumo Corp is set to report quarterly earnings on May 15, 2026, with analysts expecting EPS of $0.11 and revenue of $1.84 billion, while the stock trades near its 52-week low on the OTC market.

Terumo Corp is scheduled to report its latest quarterly results on Friday, May 15, 2026, with analysts projecting earnings per share of $0.11 and revenue of $1.84 billion, according to MarketBeat as of May 8, 2026. The upcoming release comes as the stock trades near the lower end of its 52?week range, reflecting broader pressure on the medical technology sector and recent underperformance versus peers.

On the OTC market, Terumo shares opened at about $12.31 on May 8, 2026, with a 12?month trading range of roughly $12.15 to $20.12 and a market capitalization of approximately $18.16 billion, according to MarketBeat as of May 8, 2026. Over the past year, the stock has declined by about 29.7% on its primary Tokyo listing (ticker 4543), with a 52?week range between 1,900.0 and 2,840.0 yen, per Investing.com as of May 9, 2026.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Terumo Corporation
• Sector/industry: Medical technology / healthcare equipment
• Headquarters/country: Tokyo, Japan
• Core markets: Japan, North America, Europe, Asia–Pacific
• Key revenue drivers: Cardiovascular devices, blood management systems, diabetes care products, and other medical devices
• Home exchange/listing venue: Tokyo Stock Exchange (ticker 4543); also traded in the U.S. via OTC (TRUMY)
• Trading currency: Japanese yen (JPY) on TSE; U.S. dollar (USD) on OTC

Terumo Corp: core business model

Terumo Corp is a Japan?based medical technology company that develops, manufactures, and markets a broad range of healthcare products for hospitals, clinics, and blood centers, according to MarketBeat as of May 8, 2026. The company’s portfolio spans cardiovascular devices such as catheters and stents, blood management systems including blood bags and transfusion equipment, and diabetes care products like insulin delivery systems and glucose monitoring devices.

Terumo’s business model centers on recurring demand from healthcare providers and patients, supported by long?term relationships with hospitals and distributors worldwide. The firm also invests in innovation and regulatory approvals to expand its product pipeline, particularly in minimally invasive cardiovascular therapies and advanced blood?management solutions, which are critical in aging populations and high?volume surgical settings.

Main revenue and product drivers for Terumo Corp

Cardiovascular devices and blood management systems represent the largest revenue segments for Terumo, driven by procedures such as percutaneous coronary interventions, structural heart therapies, and blood transfusions, according to sector analysis cited by AlphaSpread as of May 9, 2026. These products benefit from global trends toward minimally invasive surgery and the need for safe, efficient blood?handling technologies in both developed and emerging markets.

Diabetes care and other medical devices, including infusion systems and surgical tools, contribute additional growth levers, particularly in regions with rising diabetes prevalence and expanding healthcare infrastructure. Terumo’s diversified product mix helps mitigate dependence on any single therapy area, although the company remains exposed to pricing pressures, regulatory scrutiny, and competitive intensity from larger global med?tech peers such as Medtronic.

Why Terumo Corp matters for US investors

For US investors, Terumo offers exposure to a large, established Japanese med?tech player with significant operations in North America and Europe, according to AlphaSpread as of May 9, 2026. The company’s OTC listing (TRUMY) provides a liquid channel to participate in its growth without direct access to the Tokyo Stock Exchange, while its focus on cardiovascular and blood?management technologies aligns with long?term demand drivers in the US healthcare system.

However, Terumo’s recent underperformance versus peers such as Medtronic—down about 35% over the past 12 months compared with a 6% decline for Medtronic—highlights execution and valuation risks, according to AlphaSpread as of May 9, 2026. US investors must weigh these dynamics against the company’s innovation pipeline, including recent recognition such as the King’s Award for Innovation for Terumo Aortic’s bespoke aortic solutions, which underscores its R&D capabilities.

Conclusion

Terumo Corp is preparing to report quarterly earnings on May 15, 2026, with analysts expecting EPS of $0.11 and revenue of $1.84 billion, according to MarketBeat as of May 8, 2026. The stock trades near its 52?week low on both the Tokyo and OTC markets, reflecting sector?wide pressures and relative underperformance versus larger med?tech peers.

For US investors, Terumo offers diversified exposure to cardiovascular, blood?management, and diabetes?care technologies, but also carries currency, regulatory, and competitive risks. The upcoming earnings report and any guidance updates will be key in shaping near?term sentiment, while longer?term performance will depend on the company’s ability to sustain innovation, manage margins, and navigate pricing and reimbursement dynamics in major markets.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.